Atb Cap Markets Forecasts Cresco Labs Q2 Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF) – Stock analysts at Atb Cap Markets issued their Q2 2025 earnings per share estimates for Cresco Labs in a research report issued on Wednesday, March 12th. Atb Cap Markets analyst F. Gomes anticipates that the company will post earnings per share of ($0.03) for the quarter. Atb Cap Markets has a “Hold” rating on the stock. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Atb Cap Markets also issued estimates for Cresco Labs’ Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at ($0.03) EPS.

Cresco Labs (OTCMKTS:CRLBF) last released its quarterly earnings results on Friday, March 14th. The company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). The company had revenue of $176.00 million during the quarter, compared to analyst estimates of $172.10 million. Cresco Labs had a negative return on equity of 16.52% and a negative net margin of 9.15%.

Cresco Labs Trading Up 6.6 %

CRLBF opened at $0.75 on Friday. The firm has a market cap of $364.25 million, a P/E ratio of -3.73 and a beta of 1.79. Cresco Labs has a 12 month low of $0.70 and a 12 month high of $2.60. The company has a current ratio of 1.97, a quick ratio of 1.39 and a debt-to-equity ratio of 1.80. The stock has a 50-day moving average of $0.89 and a 200 day moving average of $1.20.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.